Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

This study is testing a combination of two treatments for metastatic melanoma (skin cancer that has spread to the liver): a liver-directed chemotherapy delivery system called Hepzato Kit, combined with two immunotherapy drugs (nivolumab and relatlimab, sold together as Opdualag). **You may be eligible if...** - You have been confirmed by biopsy to have metastatic melanoma with tumors in the liver - You have not previously received systemic (whole-body) treatment for unresectable or metastatic disease (prior adjuvant therapy is allowed if it ended more than 6 months ago) - Your tumors are measurable on imaging scans - Your organ function is adequate (based on lab tests done within 28 days) - You weigh at least 35 kg **You may NOT be eligible if...** - Your cancer has not been confirmed to involve the liver - You received systemic treatment for metastatic disease less than 6 months ago - You do not meet organ function or performance status requirements - You are too small or otherwise unsuitable for the catheter-based liver procedure Talk to your doctor to see if this trial is right for you.